Aethlon Medical, Inc. Announces Termination of Rod Kenley as President
December 07, 2018 at 12:00 pm EST
Share
Effective November 30, 2018, Rod Kenley was terminated as President of Aethlon Medical, Inc. The Board of Directors of the company has also determined to not nominate Mr. Kenley to stand for reelection as a director at the company’s annual meeting to be held in March 2019.
Aethlon Medical, Inc. (Aethlon) is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections suppression, seed the spread of metastasis and inhibit the benefit of cancer therapies. The Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression. Hemopurifier helps to bind and clear multiple different glycosylated viruses, such as human immunodeficiency virus (HIV), hepatitis C virus (HCV), Dengue, West Nile, multiple strains of influenza, Ebola, Chikungunya, smallpox, monkeypox, multiple herpes viruses, a MERS-CoV related pseudovirus, and others. Hemopurifier is used as a device for two independent indications: the treatment of individuals with advanced or metastatic cancer and the treatment of life threating viruses that are not approved therapies.
AETHLON MEDICAL, INC. 
